• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19.脓毒症和 COVID-19 病症的相似之处:对重症 COVID-19 管理的启示。
Front Immunol. 2021 Feb 3;12:602848. doi: 10.3389/fimmu.2021.602848. eCollection 2021.
2
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
3
The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?COVID-19 与脓毒症中免疫系统的失控:暴风雨前的平静?
Inflamm Res. 2020 Aug;69(8):757-763. doi: 10.1007/s00011-020-01366-6. Epub 2020 May 28.
4
COVID-19 and Sepsis.新型冠状病毒肺炎与脓毒症。
Turk J Med Sci. 2021 Dec 17;51(SI-1):3301-3311. doi: 10.3906/sag-2108-239.
5
The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.COVID-19 中的 NF-κB、炎症和细胞因子风暴三联征。
Int Immunopharmacol. 2021 Dec;101(Pt B):108255. doi: 10.1016/j.intimp.2021.108255. Epub 2021 Oct 15.
6
SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities.SARS-CoV-2 感染与氧化应激:血栓形成的病理生理学见解及治疗机会。
Cytokine Growth Factor Rev. 2022 Feb;63:44-57. doi: 10.1016/j.cytogfr.2021.11.001. Epub 2021 Nov 15.
7
Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.间充质基质细胞治疗脓毒症和脓毒性休克:治疗 COVID-19 的经验教训。
Stem Cells Transl Med. 2020 Dec;9(12):1488-1494. doi: 10.1002/sctm.20-0239. Epub 2020 Aug 18.
8
IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).白细胞介素-1(IL-1)在 COVID-19 中诱导血栓烷 A2(TxA2)的产生,导致炎症和微血栓形成:白细胞介素-1 受体拮抗剂(IL-1Ra)的抑制作用。
J Biol Regul Homeost Agents. 2020;34(5):1623-1627. doi: 10.23812/20-34-4EDIT-65.
9
Discovering common pathogenetic processes between COVID-19 and sepsis by bioinformatics and system biology approach.通过生物信息学和系统生物学方法发现 COVID-19 和脓毒症之间的共同发病机制。
Front Immunol. 2022 Aug 31;13:975848. doi: 10.3389/fimmu.2022.975848. eCollection 2022.
10
Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.细胞因子风暴:COVID-19 恶化的病理生理演变的主要决定因素。
Front Immunol. 2021 Apr 28;12:589095. doi: 10.3389/fimmu.2021.589095. eCollection 2021.

引用本文的文献

1
Minimalistic Transcriptomic Signatures Permit Accurate Early Prediction of COVID-19 Mortality.简约转录组特征可实现对 COVID-19 死亡率的准确早期预测。
medRxiv. 2025 May 19:2025.05.18.25327658. doi: 10.1101/2025.05.18.25327658.
2
Activin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis.激活素A对Smad3的激活可减轻银屑病和脓毒症小鼠模型中的先天性炎症。
J Clin Invest. 2025 Mar 11;135(9). doi: 10.1172/JCI187063. eCollection 2025 May 1.
3
Vagal nerve stimulation for the management of long COVID symptoms.迷走神经刺激术用于管理新冠长期症状
Infect Med (Beijing). 2024 Nov 8;3(4):100149. doi: 10.1016/j.imj.2024.100149. eCollection 2024 Dec.
4
COVID-19-Associated Sepsis: Potential Role of Phytochemicals as Functional Foods and Nutraceuticals.COVID-19 相关性败血症:植物化学物质作为功能性食品和营养保健品的潜在作用。
Int J Mol Sci. 2024 Aug 3;25(15):8481. doi: 10.3390/ijms25158481.
5
The Role of SARS-CoV-2 Nucleocapsidic Antigen and Krebs von den Lungen 6 Serum Levels in Predicting COVID-19 Pneumonia Outcome.严重急性呼吸综合征冠状病毒2核衣壳抗原和肺腺癌6血清水平在预测新型冠状病毒肺炎预后中的作用
Diagnostics (Basel). 2024 Mar 18;14(6):642. doi: 10.3390/diagnostics14060642.
6
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?2023 年关于 COVID-19、可能的肝脏途径和酒精滥用,我们了解多少?
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
7
The unfolded protein response pathway as a possible link in the pathogenesis of COVID-19 and sepsis.未折叠蛋白反应途径可能是 COVID-19 和脓毒症发病机制中的一个环节。
Arch Virol. 2024 Jan 8;169(2):20. doi: 10.1007/s00705-023-05948-7.
8
The role of SARS-COV-2 infection in promoting abnormal immune response and sepsis: A comparison between SARS-COV-2-related sepsis and sepsis from other causes.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染在促发异常免疫反应和脓毒症中的作用:SARS-CoV-2相关脓毒症与其他原因所致脓毒症的比较
Infect Med (Beijing). 2023 Apr 28;2(3):202-211. doi: 10.1016/j.imj.2023.04.006. eCollection 2023 Sep.
9
A hub gene signature as a therapeutic target and biomarker for sepsis and geriatric sepsis-induced ARDS concomitant with COVID-19 infection.一种作为治疗靶点和生物标志物的枢纽基因特征,用于脓毒症和老年脓毒症合并 COVID-19 感染引起的 ARDS。
Front Immunol. 2023 Sep 26;14:1257834. doi: 10.3389/fimmu.2023.1257834. eCollection 2023.
10
Identification of an Immune-Related Gene Diagnostic Model and Potential Drugs in Sepsis Using Bioinformatics and Pharmacogenomics Approaches.使用生物信息学和药物基因组学方法鉴定脓毒症中免疫相关基因诊断模型及潜在药物
Infect Drug Resist. 2023 Aug 28;16:5665-5680. doi: 10.2147/IDR.S418176. eCollection 2023.

本文引用的文献

1
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高:快速系统评价、荟萃分析,并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
2
Immunosuppressive Drugs and COVID-19: A Review.免疫抑制药物与新型冠状病毒肺炎:综述
Front Pharmacol. 2020 Aug 28;11:1333. doi: 10.3389/fphar.2020.01333. eCollection 2020.
3
Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy.新冠病毒感染所致凝血病的血液学表型:与典型脓毒症所致凝血病大不相同。
J Clin Med. 2020 Sep 5;9(9):2875. doi: 10.3390/jcm9092875.
4
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?新型冠状病毒肺炎与心血管后果:内皮功能障碍是最严峻的挑战吗?
Thromb Res. 2020 Dec;196:143-151. doi: 10.1016/j.thromres.2020.08.039. Epub 2020 Aug 27.
5
Co-infections: potentially lethal and unexplored in COVID-19.合并感染:在新冠病毒病中可能致命且未被探索。
Lancet Microbe. 2020 May;1(1):e11. doi: 10.1016/S2666-5247(20)30009-4. Epub 2020 Apr 24.
6
Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study.伦敦多家民族卫生服务信托机构中 2019 年冠状病毒病住院患者的临床特征和结局预测因素:一项回顾性队列研究。
Clin Infect Dis. 2021 Dec 6;73(11):e4047-e4057. doi: 10.1093/cid/ciaa1091.
7
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.严重 COVID-19 患者血浆中的细胞因子谱与 ARDS 和脓毒症无差异。
JCI Insight. 2020 Sep 3;5(17):140289. doi: 10.1172/jci.insight.140289.
8
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.严重的免疫抑制,而非细胞因子风暴,是 COVID-19 感染的特征。
JCI Insight. 2020 Sep 3;5(17):140329. doi: 10.1172/jci.insight.140329.
9
Editorial: The Immunology of Sepsis-Understanding Host Susceptibility, Pathogenesis of Disease, and Avenues for Future Treatment.社论:脓毒症的免疫学——理解宿主易感性、疾病发病机制及未来治疗途径
Front Immunol. 2020 Jun 23;11:1263. doi: 10.3389/fimmu.2020.01263. eCollection 2020.
10
Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.肺泡巨噬细胞功能障碍和细胞因子风暴在两例严重 COVID-19 患者发病机制中的作用。
EBioMedicine. 2020 Jul;57:102833. doi: 10.1016/j.ebiom.2020.102833. Epub 2020 Jun 20.

脓毒症和 COVID-19 病症的相似之处:对重症 COVID-19 管理的启示。

Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19.

机构信息

West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana.

Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.

出版信息

Front Immunol. 2021 Feb 3;12:602848. doi: 10.3389/fimmu.2021.602848. eCollection 2021.

DOI:10.3389/fimmu.2021.602848
PMID:33613574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7886971/
Abstract

Sepsis is a life-threatening systemic illness attributed to a dysregulated host response to infection. Sepsis is a global burden killing ~11 million persons annually. In December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and has resulted in more than 1,535,982 deaths globally as of 8 December 2020. These two conditions share many pathophysiological and clinical features. Notably, both sepsis and COVID-19 patients experience consumptive thrombocytopenia, haemolytic anaemia, vascular microthrombosis, multi-organ dysfunction syndrome, coagulopathy, septic shock, respiratory failure, fever, leukopenia, hypotension, leukocytosis, high cytokine production and high predisposition to opportunistic infections. Considering the parallels in the immunopathogenesis and pathophysiological manifestations of sepsis and COVID-19, it is highly likely that sepsis care, which has a well-established history in most health systems, could inform on COVID-19 management. In view of this, the present perspective compares the immunopathogenesis and pathophysiology of COVID-19 and non-SARS-CoV-2 induced sepsis, and lessons from sepsis that can be applicable to COVID-19 management.

摘要

脓毒症是一种危及生命的全身性疾病,其特征是宿主对感染的反应失调。脓毒症是一个全球性的负担,每年导致约 1100 万人死亡。2019 年 12 月,一种新型肺炎疾病被命名为 2019 年冠状病毒病(COVID-19),由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起,截至 2020 年 12 月 8 日,已在全球范围内导致超过 153.5982 人死亡。这两种疾病有许多病理生理学和临床特征。值得注意的是,脓毒症和 COVID-19 患者都经历消耗性血小板减少症、溶血性贫血、血管微血栓形成、多器官功能障碍综合征、凝血障碍、脓毒性休克、呼吸衰竭、发热、白细胞减少症、低血压、白细胞增多症、细胞因子大量产生和易发生机会性感染。鉴于脓毒症和 COVID-19 的免疫发病机制和病理生理表现存在相似之处,在大多数卫生系统中具有悠久历史的脓毒症治疗方法很可能为 COVID-19 的管理提供信息。有鉴于此,本观点比较了 COVID-19 和非 SARS-CoV-2 引起的脓毒症的免疫发病机制和病理生理学,并讨论了脓毒症中可应用于 COVID-19 管理的经验教训。